In comparison to circulating immune cells, tumor infiltrating lymphocytes (TILs) have a greater expression of PD1, T-cell immunoglobulin and mucin containing protein-3 (TIM-3) or Lymphocyte-Activation Gene 3 (LAG3) in imatinib-naive as well as imatinib-sensitive and resistant-tumors (55). This evidence concerns the gene LAG3 and neoplasm.